Business Description
Insmed Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
IM8N.Germany
•
INSM.Mexico
•
0JAV.UK
•
INSM.USA
Description
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.67 | |||||
| Equity-to-Asset | 0.04 | |||||
| Debt-to-Equity | 18.77 | |||||
| Debt-to-EBITDA | -2.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.95 | |||||
| Beneish M-Score | -1.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 135.9 | |||||
| 3-Year EBITDA Growth Rate | 3.8 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| 3-Year Book Growth Rate | 8.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 31.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.94 | |||||
| 9-Day RSI | 46.53 | |||||
| 14-Day RSI | 45.36 | |||||
| 6-1 Month Momentum % | 12.44 | |||||
| 12-1 Month Momentum % | -6.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.93 | |||||
| Quick Ratio | 5.34 | |||||
| Cash Ratio | 4.88 | |||||
| Days Inventory | 457.17 | |||||
| Days Sales Outstanding | 38.71 | |||||
| Days Payable | 238.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.47 | |||||
| Operating Margin % | -174.1 | |||||
| Net Margin % | -188.04 | |||||
| ROE % | -129.14 | |||||
| ROA % | -34.71 | |||||
| ROIC % | -101.13 | |||||
| ROC (Joel Greenblatt) % | -373.79 | |||||
| ROCE % | -36.18 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.97 | |||||
| PB Ratio | 55.43 | |||||
| EV-to-EBIT | -6.99 | |||||
| EV-to-Forward-EBIT | -9.33 | |||||
| EV-to-EBITDA | -7.21 | |||||
| EV-to-Forward-EBITDA | -9.57 | |||||
| EV-to-Revenue | 12.36 | |||||
| EV-to-Forward-Revenue | 8.08 | |||||
| EV-to-FCF | -8.04 | |||||
| Earnings Yield (Greenblatt) % | -14.29 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INSM
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 221.209 | ||
| EPS (TTM) ($) | -3.51 | ||
| Beta | 1.12 | ||
| Volatility % | 33.42 | ||
| 14-Day RSI | 45.36 | ||
| 14-Day ATR ($) | 1.092223 | ||
| 20-Day SMA ($) | 23.645 | ||
| 12-1 Month Momentum % | -6.6 | ||
| 52-Week Range ($) | 16.41 - 34.435 | ||
| Shares Outstanding (Mil) | 119.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insmed Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insmed Inc Analysis
Share your researchHeadlines
See More
No news.